they are considered a first-line therapy that helps maintain stable blood sugar levels, reduces the risk of long-term complications such as kidney damage and heart disease, and can also be used in conditions like polycystic ovary syndrome (PCOS) to improve insulin resistance, making them a safe and effective option when combined with proper diet and exercise
Managing and Minimizing Side Effects Taking a proactive approach to managing side effects can make a significant difference in a patients experience with GLP-1 medications
Mounjaro is administered as a once-weekly subcutaneous injection , typically starting at a low dose (2.5 mg) and gradually increasing over several weeks to minimise gastrointestinal side effects
Table of Contents The evolution of GLP-1 therapy into chronic treatment Gastrointestinal tolerability beyond three years Discontinuation trends and persistence patterns Strategies for maintaining long-term GLP-1 safety Clinical implications for chronic therapy The Evolution of GLP-1 Therapy Into Chronic Treatment In the early years of incretin-based therapy, clinicians often viewed GLP-1 receptor agonists as add-on treatments for patients with uncontrolled type 2 diabetes
In 2024, Eli Lilly launched LillyDirect, Pfizer launched PfizerForAll, and Astellas launched DIGITIVA platforms that went beyond marketing to offer integrated digital front doors connecting remote diagnosis, telehealth, e-prescribing, fulfilment, and disease management
[20] [21] Patients with type 2 diabetes inherently have a higher baseline risk of cardiovascular disease, including heart failure, making it important to distinguish between medication effects and underlying disease progression
